Blog Updates

We post biotech news, company results, and our own analysis. The free Amp blog posts are usually shortened and aren't released until a few days/weeks after they are published to our premium Amp Core blog.

To get the latest updates, company reports, and more check out our premium Amp Core membership:

November 15, 2019

Today, an advisory committee appointed by the FDA met and voted to recommend to the FDA that it expands the label for AMRN's cardiovascular drug Vascepa based on the landmark, large multi-year Reduce-It trial results, initially reported last year and published in the N...

July 2, 2019

Central nervous system (CNS) disorder drug development is a particularly difficult branch of biopharma drug development. ITCI has experienced this first hand, with inconsistent late stage results for ITI-007 (Lumateperone), a promising therapy for certain CNS disorders...

June 26, 2019

GLYC has what is likely to be a binary event reading out later this year, likely in the next 45 days, with the phase 3 readout of its partnered-out drug rivipansel for the treatment of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD). We find it...

June 14, 2019

Congrats to ARQL and especially CLL (a type of blood cancer) patients on the impressive early-stage data presented today at a poster session at the European Haematology Association annual conference, on ARQL's experimental reversible Btk kinase inhibitor, ARQL 531, for...

May 29, 2019

Congrats to CARA on a well-executed and positive Phase 3 trial of KORSUVA injection for reduction of pruritis (severe itching) in hemodialysis chronic kidney disease patients. The phase 3 top-line data met the primary endpoint of proportion of patients on KORSUVA achie...

May 21, 2019

Congrats to ARRY on positive data for mutant BRAF colorectal cancer (CRC). This interim data should lead to FDA/EMA approvals in this indication and more revenue for ARRY both short-term, because it is already listed on at least one set of guidelines, and long-term pos...

April 29, 2019

We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011. This would be good for society in our fight against the opioid crisis. Furthermore, it could be rewarding for investors too, since th...

April 17, 2019

Q2 2019 Amp Core™ Quarterly Report

Published 4/17/19


We were looking for a rebound in small/mid ("smid") cap biopharma stocks in Q1 as laid out in our Q1 '19 Report, and thankfully we got it. As we suggested in our Q1 report, there were a series of acquisitions i...

(For a longer version of this article, with more detailed legal facts, please CLICK HERE.)

Concert (CNCE) and Incyte (INCY) have been embroiled in patent disputes related to JAK inhibitors for at least the past several years. An imminent decision, due by April 9, 2019,...

Please reload

*Disclaimer: Information provided on and in any of our reports, products and services, including our Amp Core™ product, are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. 

By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.

Amp Core™ is a trademark of Amp Biotech Research, LLC

©2019 BY Amp Biotech Research